Stocks · News reference

Cytokinetics Announced The Primary Results From ACACIA-HCM (Assessment Comparing Aficamten To Placebo On Cardiac Endpoints In Adults With Non-obstructive HCM), The Pivotal Phase 3 Clinical Trial Of Aficamten In Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Aug 28, 2026, 9:48 AMBenzinga Newsdesk

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 28, 2026, 9:48 AM
Checked: Aug 28, 2026, 9:48 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 28, 2026, 5:31 PMBenzinga Newsdesk
Cytokinetics shares are trading lower. The company reported pivotal Phase 3 ACACIA‑HCM results showing aficamten met both dual primary endpoints, with significant improvements in patient quality‑of‑life scores and exercise capacity versus placebo.
Read original at benzinga
CYTK
SEC EDGARAug 28, 2026, 1:21 PMSEC EDGAR
8-K filing — CYTOKINETICS INC (CYTK)
Filed: 2026-08-28 AccNo: 0001193125-26-372456 Size: 1 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar
CYTK
BenzingaAug 20, 2026, 11:35 AMBenzinga Newsdesk
Cytokinetics Announces Primary Results From Phase 3 Trial Of Aficamten In Non-Obstructive Hypertrophic Cardiomyopathy To Be Presented August 28 At ESC Congress
Read original at benzinga
CYTK